Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07721532 | Observing the Real-world Non-interventional Study of Abiraterone Acetate Tablets (II) in Treating Chinese Patients With Metastatic Prostate Cancer(prostate) | active not recruiting | — | 3,000 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT01352429 | Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer | active not recruiting | — | 303 | Abramson Cancer Center at Penn Medicine |
| 1 |
| Jul 22, 2026 |
| clinicaltrials |
| NCT05653063 | ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer | active not recruiting | — | 1,029 | University College, LondonOTHER | 4 | Jul 22, 2026 | clinicaltrials |
| NCT04549207 | Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer | active not recruiting | Phase 4 | 240 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05416996 | A Study of Telemedicine Shared Medical Appointments (SMAs) Versus Individual Telemedicine Visits for People With Prostate Cancer | active not recruiting | — | 88 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06183905 | Multi-parametric Ultrasound Versus Multi-parametric MRI for Prostate Cancer Detection(TRUSVSMPMRI) | active not recruiting | N/A | 635 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04915508 | Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy(EXCALIBUR) | active not recruiting | Phase 2 | 165 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03999151 | Diet and Exercise Interventions Among Men With Prostate Cancer (Prostate 8-II) | active not recruiting | N/A | 204 | University of California, San FranciscoOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04267887 | Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer | active not recruiting | Phase 2 | 7 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05169970 | A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer | active not recruiting | Phase 2 | 222 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05842057 | Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy(HAMMER) | active not recruiting | Phase 2 | 118 | University of MiamiOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT00868803 | Aberrant Gene Expression Prostate Carcinoma | active not recruiting | — | 5,000 | Lahey ClinicOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT02861573 | Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | active not recruiting | Phase 1 / Phase 2 | 1,200 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 13, 2026 | clinicaltrials |
| NCT04748042 | Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) | active not recruiting | Phase 2 | 21 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05787587 | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 216 | IDEAYA BiosciencesINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05498272 | Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations(NePtune) | active not recruiting | Phase 2 | 32 | Rana McKay, MDOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06004661 | Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function | active not recruiting | Phase 2 | 23 | Novartis PharmaceuticalsINDUSTRY | 5 | Jul 10, 2026 | clinicaltrials |
| NCT01508390 | Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate | active not recruiting | N/A | 35 | Boston Medical CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT02319837 | Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | active not recruiting | Phase 3 | 1,068 | PfizerINDUSTRY | 17 | Jul 9, 2026 | clinicaltrials |
| NCT01140373 | Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) | active not recruiting | Phase 1 | 13 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04624256 | Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial(GARUDA) | active not recruiting | N/A | 208 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06029998 | Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion(BORXPTEN) | active not recruiting | Phase 2 | 22 | University of UtahOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07082049 | AI-LLM Communication Aid in Prostate Cancer Care (AI-CAP）(AI-CAP) | active not recruiting | N/A | 160 | Fudan UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04898634 | A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer | active not recruiting | Phase 1 | 216 | Janssen Research & Development, LLCINDUSTRY | 6 | Jul 6, 2026 | clinicaltrials |
| NCT07683182 | Intraprostatic Anesthesia During Transperineal Prostate Biopsy(PRO-PAIN) | active not recruiting | N/A | 50 | Marmara UniversityOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03127631 | A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients(RADICALPC) | active not recruiting | N/A | 5,000 | McMaster UniversityOTHER | 9 | Jul 2, 2026 | clinicaltrials |
| NCT04989946 | Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | University of Wisconsin, MadisonOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05628363 | Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer | active not recruiting | N/A | 28 | Washington University School of MedicineOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05288166 | A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)(CYCLONE 3) | active not recruiting | Phase 3 | 925 | Eli Lilly and CompanyINDUSTRY | 24 | Jul 1, 2026 | clinicaltrials |
| NCT04788277 | Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC) | active not recruiting | — | 810 | Thomas Jefferson UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02692105 | Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer | active not recruiting | Phase 3 | 60 | British Columbia Cancer AgencyOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05722925 | Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET | active not recruiting | Phase 4 | 50 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04619069 | Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 60 | Sunnybrook Health Sciences CentreOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05079698 | A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer | active not recruiting | Phase 1 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06599476 | Rectal Spacers in Prostate Cancer Patients Undergoing Radiation Therapy | active not recruiting | N/A | 150 | Advanced Radiation Centers of New YorkOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT02095249 | Prostate Hypoxia - TIC | active not recruiting | N/A | 39 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03254420 | Evaluation of Late Toxicity Following Intensity-Modulated Radiotherapy and Two Image-Guided Strategies With Corresponding Treatment Margins.(RCMIGI) | active not recruiting | N/A | 74 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04536805 | Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin(REPAIR) | active not recruiting | Phase 1 / Phase 2 | 44 | Institut Cancerologie de l'OuestOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06430749 | Targeted Microwave Tissue Coagulation for Prostate Cancer(MicroPro2) | active not recruiting | N/A | 65 | Osamu UkimuraOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT02918253 | HDR Focal: Feasibility Study | active not recruiting | N/A | 60 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04419402 | Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer(ENZA-p) | active not recruiting | Phase 2 | 162 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07658573 | AI Multimodal Model for Predicting CRPC Progression Risk(AI-MM_CPRC) | active not recruiting | — | 500 | Guangxi Medical UniversityOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06257264 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | active not recruiting | Phase 1 | 103 | BeiGeneINDUSTRY | 6 | Jun 18, 2026 | clinicaltrials |
| NCT06318273 | A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 | 152 | AbbVieINDUSTRY | 7 | Jun 17, 2026 | clinicaltrials |
| NCT06561230 | Leveraging EA8191 to Assess AI-Augmented EHR Abstraction | active not recruiting | — | 300 | University of PennsylvaniaOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT01950351 | Hypofractionated Proton Beam Therapy for Localized Prostate Cancer | active not recruiting | Phase 2 | 241 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05471414 | Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer(WFPBD) | active not recruiting | N/A | 76 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05683691 | Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer(VAPOR 2) | active not recruiting | N/A | 400 | Francis Medical Inc.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07597369 | Clinically Actionable Tumor-Associated Antigens in Prostate Cancer | active not recruiting | — | 1,600 | Peking University First HospitalOTHER | 1 | Jun 15, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 23, 2026source: clinicaltrials